IMMX · Immix Biopharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.98M | - | $4.58M | $3.97M | $1.98M | - | $4.45M | $2.22M | $3.25M | - |
| SG&A | $4.82M | - | $3.08M | $2.75M | $2.71M | - | $2.95M | $2.48M | $2.34M | - |
| Total Operating Expenses | $10.80M | - | $7.66M | $6.72M | $4.68M | - | $7.39M | $4.70M | $5.59M | - |
| D&A | $91.6K | - | - | - | $38.2K | - | - | - | $3.0K | - |
| Operating Income | ($10.80M) | - | ($7.66M) | ($6.72M) | ($4.68M) | - | ($7.39M) | ($4.70M) | ($5.59M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | $7.7K | $8.9K | $9.8K | - | $11.1K | $10.3K | $8.8K | - |
| Net Income | ($10.09M) | - | ($7.59M) | ($6.62M) | ($4.54M) | - | ($7.15M) | ($4.39M) | ($5.26M) | - |
| EPS - Basic | ($0.18) | - | ($0.24) | ($0.22) | ($0.15) | - | ($0.24) | ($0.15) | ($0.22) | - |
| EPS - Diluted | ($0.18) | - | ($0.24) | ($0.22) | ($0.15) | - | ($0.24) | ($0.15) | ($0.22) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $79.25M | $93.93M | $15.95M | $11.64M | $15.92M | $17.68M | $19.69M | $23.98M | $29.32M | $17.51M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.73M | $5.44M | $7.05M | $6.61M | $5.74M | $5.39M | $3.29M | $2.35M | $3.51M | $1.43M |
| Current Assets | $92.27M | $101.24M | $16.58M | $12.33M | $16.78M | $20.20M | $22.76M | $27.33M | $32.92M | $19.79M |
| Total Assets | $95.82M | $104.84M | $20.08M | $15.64M | $19.89M | $22.95M | $25.14M | $28.84M | $34.35M | $19.93M |
| Current Liabilities | $10.54M | $10.11M | $10.85M | $10.01M | $9.31M | $8.69M | $6.56M | $3.90M | $5.66M | $3.72M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $11.45M | $11.04M | $11.82M | $10.98M | $10.30M | $9.70M | $7.59M | $4.94M | $6.72M | $3.72M |
| Stockholders' Equity | $93.80M | $93.80M | $8.26M | $4.65M | $9.59M | $13.25M | $17.55M | $23.89M | $27.92M | $16.41M |
| Retained Earnings | ($114.55M) | ($104.46M) | ($93.78M) | ($86.19M) | ($79.57M) | ($75.02M) | ($70.21M) | ($63.06M) | ($58.67M) | ($53.41M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.83M) | - | - | - | ($1.69M) | - | - | - | ($3.83M) | - |
| Investing Cash Flow | ($4.80M) | - | - | - | ($67.7K) | - | - | - | ($301.9K) | - |
| Financing Cash Flow | ($37.6K) | - | - | - | - | - | - | - | $15.95M | - |
| CapEx | $32.5K | - | - | - | $67.7K | - | - | - | $301.9K | - |
| Free Cash Flow | ($9.86M) | - | - | - | ($1.75M) | - | - | - | ($4.13M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.98 | - | - | - | 0.39 | - | - | - | 0.79 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.5% | - | -37.8% | -42.4% | -22.8% | - | -28.4% | -15.2% | -15.3% | - |
| Return on equity | -10.8% | - | -91.8% | -142.3% | -47.3% | - | -40.7% | -18.4% | -18.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 8.76 | 10.01 | 1.53 | 1.23 | 1.80 | 2.33 | 3.47 | 7.00 | 5.82 | 5.32 |
| Quick ratio | 8.76 | 10.01 | 1.53 | 1.23 | 1.80 | 2.33 | 3.47 | 7.00 | 5.82 | 5.32 |
| Cash ratio | 7.52 | 9.29 | 1.47 | 1.16 | 1.71 | 2.04 | 3.00 | 6.14 | 5.18 | 4.70 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.02 | 1.12 | 2.43 | 3.36 | 2.07 | 1.73 | 1.43 | 1.21 | 1.23 | 1.21 |
| Liabilities / Assets | 0.12 | 0.11 | 0.59 | 0.70 | 0.52 | 0.42 | 0.30 | 0.17 | 0.20 | 0.19 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 5.4x | - | 8.1x | 13.3x | 5.2x | - | 2.5x | 2.4x | 2.6x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -130.7% | - | -3.6% | -42.9% | 16.2% | - | -63.5% | -26.4% | -121.8% | - |
| Net income growth (YoY) | -122.1% | - | -6.1% | -50.8% | 13.6% | - | -67.0% | -22.8% | -112.1% | - |
| EPS growth (YoY) | -20.0% | - | 0.0% | -46.7% | 31.8% | - | -4.3% | 37.5% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -462.5% | - | - | - | 57.5% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 877.7% | 607.8% | -52.9% | -80.5% | -65.6% | -19.2% | -11.2% | 80.6% | 112.1% | 24.7% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Immix Biopharma against the 5 most active filers in the same SIC group.